Original-Research: Defence Therapeutics Inc. (von GBC AG): BUY

    ^

Original-Research: Defence Therapeutics Inc. - von GBC AG

Einstufung von GBC AG zu Defence Therapeutics Inc.

Unternehmen: Defence Therapeutics Inc.
ISIN: CA24463V1013

Anlass der Studie: Research Report (Initial Coverage)
Empfehlung: BUY
Kursziel: 11,02 CAD (7,06 EUR)
Kursziel auf Sicht von: 31.12.2022
Letzte Ratingänderung: 
Analyst: Julien Desrosiers, Cosmin Filker

Uniquely Positioned with versatile ACCUM(TM); Enormous upside potential;
Next generation of cancer treatment
 
  - Proprietary platform technology with proven enhanced intracellular
    delivery. Promotes delivery of target product without non-specific
    protein/antigen degradation or interference.
 
  - Strong versatility of the Accum(TM) platform. The company has published
    promising pre-clinical results in eleven different indications with
    various applications in ADCs, Cancer Vaccines, and ID Vaccines.
 
  - Uniquely positioned. Accum(TM) technology is the next generation of
    cancer treatment.
 
  - Massive upside potential. All their current research is pre-clinical
    and have shown remarkable results.
 
  - Growth opportunity. The company is far from done unlocking the full
    potential of Accum(TM) technology.
 
 
  - Attractive capital structure. The company has only 47.0M shares fully
    diluted
 
  - Well financed. The company has currently enough cash on hand to
    complete their planned Phase I studies.
 
  - Strong and Extensive experienced team in pre-clinical/clinical,
    business development, CMC and regulatory.
 
 
  - Major milestones to be achieved within the next 6-12 months with many
    GLP ongoing studies and planned filing of Phase I studies for both
    Melanoma and breast cancer.
 
  - Flexible business model: From royalties to JVs or full development.
    Accum(TM) technology allows for an optimized business model for each
    indication and possible near-term revenues.
 
  - Based on our DCF model we have determine a price target of 11.02 CAD
    (7.60 EUR) per share and a BUY rating.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/23350.pdf

Kontakt für Rückfragen
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
++++++++++++++++

Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,5b,6a,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:

http://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
Date and time of completion of the study: 09/02/2022 (9:32 pm)
Date and time of first transmission: 10/02/2022 (11:00 am)

-------------------übermittelt durch die EQS Group AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. 
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

°